Lumigan (bimatoprost) / Senju, AbbVie 
Welcome,         Profile    Billing    Logout  
 0 Diseases   17 Trials   17 Trials   629 News 


12345678910»
  • ||||||||||  latanoprost / Generic mfg., Lumigan (bimatoprost) / Senju, AbbVie, travoprost ophthalmic / Generic mfg.
    Journal:  Predictors of severity in prostaglandin-associated periorbitopathy. (Pubmed Central) -  Mar 9, 2025   
    Older age, longer duration of PGA therapy, and the use of bimatoprost and travoprost were significant and independent predictors of severe PAP in patients with glaucoma. Patients with these risk factors should be identified and managed to prevent the development of severe PAP.
  • ||||||||||  clobetasol propionate topical / Generic mfg.
    Network meta-analysis based comparison of topical treatments for vitiligo () -  Feb 21, 2025 - Abstract #AAD2025AAD_2237;    
    Patients with these risk factors should be identified and managed to prevent the development of severe PAP. Compared to placebo, the most effective monotherapies for achieving ?50% repigmentation were 0.1% mometasone (risk ratio [RR], 13.12; 95% confidence interval [CI], 3.86
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
    Journal:  Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS. (Pubmed Central) -  Dec 7, 2024   
    Additionally, using the Analytical GREEnness calculator and complex green analytical procedure index tools, we confirmed that the method using the DES was greener than the other methods. In this study, we developed an analytical method for illicit compounds contained in eyelash growth serums, offering an eco-friendly approach for the prevention of the distribution of illegal cosmetics.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Retrospective data, Review, Journal:  Bimatoprost for the management of vitiligo: A systematic review and meta-analysis. (Pubmed Central) -  Dec 4, 2024   
    In this study, we developed an analytical method for illicit compounds contained in eyelash growth serums, offering an eco-friendly approach for the prevention of the distribution of illegal cosmetics. No abstract available
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Journal:  Hypopigmented Burn Scar Successfully Repigmented With Noninvasive Topical Bimatoprost Treatment. (Pubmed Central) -  Nov 26, 2024   
    Here, we document the first reported case of successful improvement of a hypopigmented scar from a burn treated with topical bimatoprost 0.03% ophthalmic solution alone. We are hopeful that this will give a noninvasive option for patients who are looking to improve hypopigmented scars.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) -  Oct 10, 2024   
    P3,  N=500, Completed, 
    We did not find significant differences in enophthalmos measurements, orbital fat volume, total muscle volume, and optic nerve volume between the PGA-treated and untreated eyes. Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jul 2025 --> Oct 2024
  • ||||||||||  AGN-193408 / AbbVie
    Trial completion date, Trial primary completion date:  AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) -  Sep 22, 2024   
    P1/2,  N=96, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jul 2025 --> Oct 2024 Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Aug 2027 --> Aug 2028
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
    Journal, Adverse events:  Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database. (Pubmed Central) -  Sep 1, 2024   
    Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Aug 2027 --> Aug 2028 Our findings have revealed a potential relationship due to the biological plausibility among malignant mediastinal neoplasm, full blood count abnormal, blood immunoglobulin E increased, diabetes mellitus, blepharospasm, cataracts, chest discomfort and dry mouth; therefore, it is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk.
  • ||||||||||  dorzolamide/timolol / Generic mfg.
    Enrollment change, Trial termination:  How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (clinicaltrials.gov) -  Aug 23, 2024   
    P4,  N=36, Terminated, 
    Our findings have revealed a potential relationship due to the biological plausibility among malignant mediastinal neoplasm, full blood count abnormal, blood immunoglobulin E increased, diabetes mellitus, blepharospasm, cataracts, chest discomfort and dry mouth; therefore, it is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk. N=60 --> 36 | Recruiting --> Terminated; The 95% confidence interval for non-inferiority was met before planned enrollment was reached.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Overcoming the psychological distress of madarosis : Bimatoprost as a Source of Hope (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_5143;    
    Current evidence is of low quality due to the small sample size but is promising regarding the effectiveness of bimatoprost ophthalmic solution in promoting eyebrow regrowth. Furthermore, this effectiveness may help alleviate stress and emotional anxiety, which are exacerbating factors in alopecia.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Alopecia areata: A novel therapeutic approach (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_3773;    
    Furthermore, this effectiveness may help alleviate stress and emotional anxiety, which are exacerbating factors in alopecia. These findings suggest that the combination of Bimatoprost 0,03% solution with fractional CO2 laser therapy may represent a promising treatment modality for AA, offering enhanced efficacy in terms of both treatment response and aesthetic outcomes.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Trial completion date, Trial primary completion date:  Bimatoprost as a Treatment for Graves' Orbitopathy (clinicaltrials.gov) -  Jul 17, 2024   
    P1,  N=3, Recruiting, 
    With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma. Trial completion date: Jul 2027 --> Jul 2030 | Trial primary completion date: Jul 2024 --> Jul 2028
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Journal:  Hair Growth Promoting Effects of 15-Hydroxyprostaglandin Dehydrogenase Inhibitor in Human Follicle Dermal Papilla Cells. (Pubmed Central) -  Jul 13, 2024   
    Prostaglandin E2 (PGE2) is known to be effective in regenerating tissues, and bimatoprost, an analog of PGF2?, has been approved by the FDA as an eyelash growth promoter and has been proven effective in human hair follicles...We also revealed that DPP significantly enhanced the size of the three-dimensional spheroid in DHT-damaged HFDPCs and increased hair growth in ex vivo human hair follicle organ culture. These data suggest that DPP exhibits beneficial effects on DHT-damaged HFDPCs and can be utilized as a promising agent for improving hair loss.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) -  Jun 23, 2024   
    P3,  N=500, Active, not recruiting, 
    These data suggest that DPP exhibits beneficial effects on DHT-damaged HFDPCs and can be utilized as a promising agent for improving hair loss. Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Review, Journal:  Eyelash serums: A comprehensive review. (Pubmed Central) -  Jun 19, 2024   
    Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 As the cosmeceutical market for eyelash serums is growing, dermatologists need to be knowledgeable about evidence-based information regarding prescription and over-the-counter eyelash serum products before making recommendations to patients.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Trial completion date:  Bimatoprost as a Treatment for Graves' Orbitopathy (clinicaltrials.gov) -  May 20, 2024   
    P1,  N=3, Recruiting, 
    Our study demonstrated that 0.01% topical bimatoprost gel in combination with excimer light is considered safe and effective as treatment of nonsegmental facial vitiligo with comparable results to 0.1% tacrolimus. Trial completion date: Jul 2024 --> Jul 2027
  • ||||||||||  Psoralen / EMD Serono, Lumigan (bimatoprost) / Senju, AbbVie
    Review, Journal:  Non-surgical treatment of post-burn hypopigmentation: a literature review. (Pubmed Central) -  May 6, 2024   
    Electrophoto-Biomodulation or E light (combining intensive pulsed light, radiofrequency, and cooling), topical daylight psoralen UVA therapy, and lasers (Fractional lasers using pulse energies or CO2FL devices, lasers-assisted drug delivery as local bimatoprost and tretinoin or pimecrolimus) have been explored with encouraging results in hypopigmented burns. Finally, other promising medical strategies include using FK506, a nonsteroidal anti-inflammatory drug, to induce melanogenesis or using melanocyte-stimulating hormones with fractional laser-assisted drug deliveries, which are expected to emerge soon.
  • ||||||||||  metformin / Generic mfg.
    Journal:  Causal association of metformin treatment with diverse cardiovascular diseases: a Mendelian randomization analysis. (Pubmed Central) -  Apr 29, 2024   
    Finally, other promising medical strategies include using FK506, a nonsteroidal anti-inflammatory drug, to induce melanogenesis or using melanocyte-stimulating hormones with fractional laser-assisted drug deliveries, which are expected to emerge soon. The MR study discovered from a genetic standpoint that metformin may lower the risk of hypertrophic cardiomyopathy and valvular heart disease, yet it could elevate the risk of myocardial infarction.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Journal:  Label-Free Composition Analysis of Supramolecular Polymer-Nanoparticle Hydrogels by Reversed-Phase Liquid Chromatography Coupled with a Charged Aerosol Detector. (Pubmed Central) -  Apr 17, 2024   
    The hydrogel studied consists of modified hydroxypropylmethylcellulose, self-assembled PEG-b-PLA nanoparticles, and a therapeutic compound, bimatoprost...Moreover, this method can be used to monitor polymer degradation and material stability, which can be further elucidated by coupling the RPLC method with (1) a multi-angle light scattering detector (RPLC-MALS) or (2) high resolution mass spectrometry (RPLC-MS) and a Fourier-transform based deconvolution algorithm. We envision that this analytical strategy could be generalized to characterize critical quality attributes of other classes of supramolecular hydrogels, establish structure-property relationships, and provide rational design guidance in hydrogel drug product development.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    National Costs of Prescription Drug Market Exclusivity Extensions () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_520;    
    We focused on four drugs from distinct disease areas that experienced generic entry between 2014-2018 as case studies: imatinib (cancer), glatiramer (multiple sclerosis), celecoxib (arthritis), and bimatoprost (glaucoma). Policies to curb strategies to promote timely generic availability and avoid extending market exclusivity beyond the patent on a drug
  • ||||||||||  bimatoprost grenod (NCX 470) / Nicox
    Enrollment open, Phase classification, Trial completion date, Trial primary completion date:  Whistler: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (clinicaltrials.gov) -  Jan 11, 2024   
    P2/3,  N=20, Recruiting, 
    This positions compound 26a as a promising candidate for the development of a novel anti-glaucoma medication. Not yet recruiting --> Recruiting | Phase classification: P3b --> P2/3 | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) -  Dec 31, 2023   
    P3,  N=500, Active, not recruiting, 
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Preclinical, Journal:  Effect of retrobulbar prostaglandin analog injection on orbital fat in rats. (Pubmed Central) -  Dec 17, 2023   
    No significant fat atrophy was noted in this rat model three weeks after retrobulbar injection of PAs. To evaluate retrobulbar injection of PA as a potential therapy for orbital diseases with fat proliferation, in vivo studies in different animal models, higher concentrations of PA, or longer follow-up duration are required.